(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes

Similar documents
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Nottingham Patterns of liver fibrosis and their clinical significance

Steatotic liver disease

Improving Access to Quality Medical Care Webinar Series

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Liver Pathology in the 0bese

Index. Note: Page numbers of article titles are in boldface type.

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Chapter 18 Liver and Gallbladder

Challenges in the Diagnosis of Steatohepatitis

Paneth Cells. Road Map to the Finish. No Review this Friday. Today 11/29 Finish digestion/accessory organs. Wednesday 12/1 Immune System I

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

British Liver Transplant Group Pathology meeting September Leeds cases

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

HISTOPL4THOLOG1CAL STUDY OF LIVER

WEIGHT LOSS SURGERY A Primer on Current Options and Outcomes. Caitlin A. Halbert DO, MS, FACS, FASMBS April 5, 2018

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

NASH Bench to Bedside

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Digestive system L 4. Lecturer Dr. Firdous M. Jaafar Department of Anatomy/Histology section

Non-Alcoholic Fatty Liver Disease An Update

Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD

Access to Proven Therapies

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 )

HOW THE MICROBIOME AFFECTS OUR HEALTH

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

Week 3 The Pancreas: Pancreatic ph buffering:

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance

Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis

METABOLIC SYNDROME AND HCV: FROM HCV

NONALCOHOLIC FATTY LIVER DISEASE

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

LIVER PHYSIOLOGY AND DISEASE

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust

Clinical Staging for Obesity. Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta

Conflicts of Interest in the last 12 months

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

Not over when the surgery is done: surgical complications of obesity

Histopathology: Cell necrosis and cytoplasmic accumulations

Pathology of Fatty Liver Disease

Fat Metabolism, Insulin and MTHFR

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Obesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona

Lipids digestion and absorption, Biochemistry II

Improving the Lives of Patients with Liver Diseases

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Prelab #4 BLOOD; BONE MARROW; RESPIRATORY; INTEGUEMENT Page 1

The Growing Epidemic of Diabetes

AMR in Liver Transplantation: Incidence

UC SF. Liver and Gastrointestinal Pathology Update. University of California San Francisco. September 3, 2009

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Liver and gall bladder curriculum for ST1, presented at Northern block teaching, January 2017.

Hormonal regulation of. Physiology Department Medical School, University of Sumatera Utara

Autoimmune Hepatitis: Histopathology

NAFLD & NASH: Russian perspective

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

Understanding your FibroScan Results

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

CHAPTER 1. Alcoholic Liver Disease

Occlusive Venous Lesions in Alcoholic Liver Disease

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Metabolic defects underlying dyslipidemia in abdominal obesity

AASLD: Boston Rob Goldin

MICROSCOPIC STRUCTURE OF LIVER, GALLBLADDER, GALL DUCTS, AND PANCREAS OVERVIEW OF DEVELOPMENT OF THE ALIMENTARY CANAL

[Sem Liver Disease 21(1):81-88, Thieme Medical Publishers, Inc.]

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

Targeting Inflammation in Breast Cancer Pathogenesis

LIVER DISEASES. Pathology Department, Zhejiang University School of Medicine,

Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis. Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K.

Interesting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine

METABOLISM of ADIPOSE TISSUE

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION

Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative

2014 CURRENT ISSUES IN PATHOLOGY

-sheet 3. -Waseem Alhaj. Maha Shomaf

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

The health risks associated with obesity are widespread and

Page 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

University of Warwick institutional repository:

Liver Fat Quantification

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

HOW TO DEFINE GOOD BIOMARKERS OF HEALTH? Suzan Wopereis

Transcription:

(A) (B) (C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes representing the minimal histological criteria of steatohepatitis) are evident in the centrilobular region (C). (B) Hepatocyte ballooning and intracellular Mallory Denk bodies (arrow) are shown at high magnification. (C) The characteristic pericellular/perisinusoidal chicken wire pattern of fibrosis surrounding centrilobular hepatocytes is seen on this trichrome stain (A and B, hematoxylin and eosin stain; C: Masson trichrome stain). Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, First Edition. Edited by Roger Williams and Simon D. Taylor-Robinson. 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.

(A) (B) (C) Fig 5.2 Cryptogenic cirrhosis due to NAFLD. (A) Cirrhosis without fat is seen at low magnification. Portal tracts and fibrous septa contain mild to moderate chronic inflammatory cell infiltrates, rendering a superficial resemblance to chronic hepatitis. However, careful examination of the hepatocytes located at the periphery of the nodules (arrow) allows recognition of remaining NASH features (seen at high power in panel B). (B) High magnification of the parenchyma near the arrow in panel A. Hepatocytes are variably ballooned and there is robust Mallory Denk body formation (arrows). (C): Occasional periportal/periseptal hepatocytes show glycogenated nuclei (arrows) (A, B, and C: hematoxylin and eosin stain).

Injury and death Dying hepatocytes Hepatocytes Release Hedgehog ligands Quiescent hepatic stellate cell Cholangiocytes/ ductular progenitors Release Hedgehog ligands Immune cells Release Hedgehog ligands Activated hepatic stellate cell/myofibroblast Fig 8.1 Link between cell death and fibrogenic liver repair. Liver cell injury or death from lipotoxicity, oxidative stress and immune imbalance leads to the release of signalling factors (such as Hedgehog ligands), which promote the proliferation of ductular progenitors and liver pericytes (hepatic stellate cells) as part of the repair response. Stimulated hepatic stellate cells transition into collagenproducing myofibroblasts, and ductular progenitor cells secrete high levels of cytokines and growth factors that recruit immune cells into the liver. In turn, recruited immune cells secrete even more cytokines and growth factors that perpetuate the inflammatory and fibrogenic response. Ductular progenitors may also undergo direct differentiation into scar producing myofibroblasts.

(A) (B) (C) (D) Fig 9.1 Non-alcoholic fatty liver disease. Examples of the zone 3 and zone 1 injury patterns. (A) Typical steatohepatitis with perivenular inflammation and ballooning (arrows). (B) Masson trichrome stain from the same case showing delicate zone 3 perisinusoidal fibrosis. (C) Zone 1 borderline pattern with periportal steatosis and portal inflammation. No injury is seen around the terminal hepatic venule (arrowhead). (D) Masson trichrome stain from the same case showing periportal fibrosis but no perivenular fibrosis (arrowhead).

(A) (B) (C) (D) Fig 9.2 Alcoholic liver disease. (A) This is an example of alcoholic steatohepatitis. Steatosis is apparent along the right side; marked ballooning and Mallory Denk bodies are noted in hepatocytes along the left. Satellitosis is also seen as well as ductular reaction. (B D) These figures are from a patient who presented with signs and symptoms of venous outflow obstruction. (B) In this example of several alcoholic hepatitis, there is very little steatosis, and one can appreciate near obliteration of all vascular (terminal hepatic venule and portal tract) structures. The primary component of the cellular infiltrate is neutrophils. With close inspection, Mallory Denk bodies can be seen, as well as bile stained hepatocytes. This is an example of sclerosing hyaline necrosis and would not be seen in NAFLD/ NASH. (C) A low power trichrome stain shows obliterative fibrosis of a centrilobular region; this extent and type of fibrotic response are not described in NAFLD/NASH. (D) The high power view of the Masson trichrome highlights the remnant of a terminal hepatic venule centrally and dense sinusoidal fibrosis in the lobules. Capillarization to this extent in alcoholic liver disease results in portal hypertension without the classic histologic features of cirrhosis.

Adipose Weight gain Adipose tissue expansion Macrophage infiltration TNF-α IL-6 Insulin resistance Lipolysis FFA generation Leptin Adiponectin Adipose Liver Pancreas Insulin sensitivity Pancreatic beta cell loss Hepatic insulin sensitivity Inflammation SREBP-1-mediated lipogenesis β-oxidation of fatty acids Fig 10.1 Weight gain leads to adipose tissue expansion and inflammation, which results in a proinflammatory state. These adipokines worsen adipose tissue and hepatic and systemic insulin resistance. The deterioration in insulin sensitivity leads to pancreatic β cell loss, de novo lipogenesis, and hepatic steatosis.

FFA pool TG synthesis VLDL secretion Hepatic insulin sensitivity Simple steatosis Intestinal microbiome Kupffer cell activation hscrp LPS Steatohepatitis Polysaccharide SCFA SCFA SCFA SCFA LPS LPS LPS LPS Constituent low-grade endotoxemia LPS LPS (Metabolic endotoxemia) Adipose tissue Increased intestinal permeability Expansion inflammation decreased insulin sensitivity Small intestinal bacterial overgrowth Disruption of tight junctions Intestinal lumen Intestinal epithelium Portal vein Fig 10.2 NAFLD is associated with an increase in small intestinal bacterial overgrowth (SIBO). The intestinal microbiome breaks down polysaccharides into short chain fatty acids (SCFAs), and increased bacterial productions (i.e., LPS) are then readily absorbed into the portal circulation. These by products of digestion and intestinal microbiome subsequently influence insulin resistance and hepatic triglyceride synthesis and impair hepatic triglyceride synthesis leading to hepatic steatosis.

Gut lumen Dietary intake Choline Choline Phosphatidylcholine Availability Choline VLDL secretion Intrahepatic TG accumulation Microbiome Metabolism Methylamine Hepatotoxicity Fig 10.3 The gut microbiota catalyzes the conversion of dietary choline into methylamines, which enter the portal circulation and promote hepatocellular injury. The conversion of choline to methylamines also reduces the bioavailability of choline, leading to phosphatidylcholine deficiency, which impairs VLDL secretion and promotes steatosis. Fig 16.7 The hepatic fat fraction (HFF) map calculated using water and fat separation GRE images. The color scale on the side indicates the percent HFF. 100 90 80 70 60 50 40 30 20 10 0

100 90 80 70 60 50 40 30 20 10 Fig 16.8 Proton density hepatic fat fraction (PD HFF) map of the entire liver. The color scale on the side indicates the percent HFF. 0 Freq diff = 446.2786 Hz: or 3.4916 ppm Fig 16.10 Single voxel proton MR spectroscopy of a fatty liver at 1.5 T. Note the small red voxel placed in the right lobe of the liver and the water (arrowhead) and dominant fat (methylene) (arrow) peaks in the sampled parenchyma.

(A) (B) Fig 17.1 (A) Liver biopsy section with H&E staining at 200 magnification, showing simple severe steatosis. (B) Liver biopsy section with H&E staining at 400 magnification, showing non alcoholic steatohepatitis with ballooning, Mallory s hyaline, glycogenated nuclei, portal and lobular inflammation (Source: Courtesy of Dr Eve Fryer, Oxford University Hospitals NHS Trust).

Pulmonary Hypoventilation Obstructive sleep apnoea Asthma Dermatological Hirsutism Sweating Psoriasis Gastrointestinal Gall stones Non-Alcoholic fatty liver Colon cancer Gastro oesophageal reflux Oesophageal cancer Periodontal disease Gynaecological/obstetric Oligomenorrhea Infertility Cancer of uterus, breast, cervix Pregnancy morbidity CNS Intracranial hypertension Migraine/headache Stroke Psychological/Psychiatric Dementia Cardiovascular Hypertension Ischaemic heart disease Heart failure Thromboembolism Metabolic Diabetes Dyslipaemia Hyperinsulinaemia Musculo skeletal Osteoarthritis Gout Andrology Hypogonadism Prostate cancer Fig 19.1 The spectrum of disease linked to overweight and obesity ( Source: Science Photo Library C007/2245 (Obese woman, MRI scan). Reproduced with permission from Science Photo Library).

Fig 22.1 Gastric bypass. Fig 22.2 Sleeve gastrectomy. Me DNA methylation Lifestyles Diseases Nutrition Me Me Methylation pattern Me Histone modification Lifestyles Diseases Nutrition Methylation pattern Others Chromatin remodeling microrna Fig 26.1 The main epigenetic reactions are the methylation of CpG sites and the modifications on amino acidic tails of histones such as by methylation, acetylation or phosphorylation. These reactions could be influenced by factors such as lifestyles, diseases and diet, and the final conformation of DNA could facilitate joining of the transcription factors (Source: (left) Qiu [40], reproduced with permission of Nature Publishing Group and (right) Cordero et al. [41]).